Ma C, et al. - This trial encompassed a characterization of the γ-aminobutyric acid type A receptor pharmacology of the novel etomidate analog naphthalene-etomidate, for the development of anesthetic-selective competitive antagonists. The inference drawn was that naphthalene-etomidate was a very low-efficacy etomidate analog, which illustrated the pharmacology of an anesthetic competitive antagonist at the γ-aminobutyric acid type A receptor.